FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
11 letters match. Newest first.
-
DrugsLovelace Biomedical Research Institute
Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.
Medium -
DrugsHealthPartners Neuroscience Center Research and Innovation
FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.
Medium -
DrugsVedic Lifesciences Pvt. Ltd.
FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.
Medium -
DevicesPalamur Biosciences Private Limited
FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.
High risk -
DevicesJiangsu Kerbio Medical Technology Group Co.
FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.
High risk -
DevicesCCIC Huatongwei International Inspection Co., Ltd.
FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.
High risk -
DevicesMid-Link Testing Company, Ltd
FDA warns Mid-Link Testing over unreliable Good Laboratory Practice (GLP) safety data for medical device tests.
High risk -
DevicesSanitation & Environmental Technology Institute dba SDWH
FDA found GLP violations in SDWH's nonclinical testing of medical devices, raising doubts about safety data.
High risk -
DrugsSamm Solutions, Inc., d.b.a. BTS Research
Samm Solutions/BTS Research failed good laboratory practice (GLP) rules for nonclinical drug studies, FDA says.
Medium -
BiologicsValley Biosystems
FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.
High risk -
BiologicsToxikon Corporation/Labcorp Bedford LLC
FDA warned Toxikon/Labcorp Bedford over GLP violations in a biologics nonclinical study, including incorrect kidney-function calculations and failed QA review.
Medium